Conference Call with Divi's Laboratories Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Divi's Laboratories announced Q3FY25 results Consolidated total income Rs 2,401 crore for Q3FY25 as against a consolidated total income of Rs 1,950 crore for Q3FY24. Profit before tax (PBT) for Q3FY25 amounted to Rs 726 crore as against a PBT of Rs 489 crore for Q3FY24. Profit after tax (PAT) for Q3FY25 amounted to Rs 589 crore as against a PAT of Rs 358 crore for Q3FY24. For the Q3FY25, we have forex gain of Rs 10 crore as against a gain of Rs 18 crore during Q3FY24. Result PDF
Pharmaceuticals company Divi's Laboratories announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Consolidated total income Rs 2,444 crore for Q2FY25 as against a consolidated total income of Rs 1,995 crore for Q2FY24. Profit before tax (PBT) for the Q2FY25 amounted to Rs 722 crore as against a PBT of Rs 469 crore for Q2FY24. Profit after tax (PAT) for the Q2FY25 amounted to Rs 510 crore as against a PAT of Rs 348 crore for Q2FY24. Forex gain of Rs 29 crore as against a gain of Rs 11 crore during Q2FY24. H1FY25 Financial Highlights: Consolidated total income of Rs 4,640 crore as against a consolidated total income of Rs 3,854 crore during H1FY24. PBT for H1FY25 came to Rs 1,326 crore as against Rs 961 crore for H1FY24. PAT for H1FY25 came to Rs 940 crore as against Rs 704 crore for H1FY24. Forex gain of Rs 28 crore against a gain of Rs 14 crore for H1FY24. Result PDF